Skip to main content
OpenTrials
Completed

NCT Number: NCT04348734

Management of Parapneumonic Pleurisy Guided by an Early Pleural Ultrasound

Parapneumonic pleurisies are a frequent complication of pneumopathies, but therapeutic management is poorly codified. Only the indication of thoracic drainage has benefited from expert recommendations. However, we find in the literature the major importance of early management of infectious pleurisy in order to minimize the sequelae. Pleural ultrasound, sensitive and specific in this pathology could bring us a real interest in terms of diagnostic speed and therefore of care. This study therefore seeks to show that pleural ultrasound can have a major interest in improving the management of patients with parapneumonic pleurisy, by reducing the number of medical treatment failures.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chu Amiens, Amiens, France

Loading trial locations.

About this study

This is a prospective, multicentre, non-randomized study evaluating routine care, which includes all patients hospitalized in the departments participating in the study, for pneumonia with or without pleurisy. Patients benefiting from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm. In case of pleural effusion of type 1, the type of treatment will be left to the appreciation of the clinician (puncture or drainage), in case of pleural effusion of type 2, 3 or 4 the patient benefited from pleural drainage.

Patients included in the study will benefit from a pleural ultrasound on the day of their hospitalization, up to 96 hours after treatment. Ultrasound will then allow us to look for the presence of pleural effusion. In the event of effusion corresponding to a parapneumonic effusion or purulent pleurisy, the conduct to be followed will be defined according to the ultrasound type of effusion. Types 1 will benefit from an evacuating pleural puncture or drainage, depending on the clinician's judgment. Types 2, 3, and 4 will benefit from weeping drainage.

the target population: adult patients, hospitalized for pneumonia or confirmed pleurisy, by imaging and exploratory pleural puncture in the departments participating in the study over the period concerned The main outcome measure is the failure of medical treatment, defined as the need to resort to surgery, with or without peeling, or death secondary to pleurisy. The secondary endpoint is the presence of radiological sequelae at 3 months and 6 months defined by a retraction of the hemithorax concerned with pachypleuritis or an ascent of the diaphragmatic dome or the persistence of pleurisy

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult patients, hospitalized for pneumonia or confirmed pleurisy, by imaging and exploratory pleural puncture.
  • Patients affiliated to social security

Exclusion criteria

  • patients with transudative pleurisy,
  • patients with exudative pleurisy in the context of pulmonary neoplasia or tuberculosis,
  • patients with pneumonectomy compartment infections,
  • Patient under guardianship or curatorship,
  • Subjects under 18 years of age,
  • Pregnant women,
  • patients in emergency situations

Treatment and study plan

pleural ultrasound

Diagnostic Test

Patients will benefit from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm

Primary outcomes

  1. interet de l'échographie pleurale dans les pleurésies parapneumoniques

    Time frame: 1 year

    Evaluate the failure of medical treatment, defined as the need to resort to surgery, or death secondary to pleuris

Secondary outcomes

  1. presence radiological sequelae a pleural effusion at 3 months

    Time frame: 3 months

    the presence of radiological sequelae at 3 months defined by a retraction of the hemithorax concerned with pachypleuritis or an ascent of the diaphragmatic dome or the persistence of a pleural effusion

  2. presence radiological sequelae a pleural effusion at 6 months

    Time frame: 6 months

    the presence of radiological sequelae at 6 months defined by a retraction of the hemithorax concerned with pachypleuritis or an ascent of the diaphragmatic dome or the persistence of a pleural effusion

Sponsors and collaborators

Lead sponsor

Central Hospital Saint Quentin

Other Gov

Collaborators

  • Amiens University Hospital

Registry information

Acronym: ECHOPP

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Apr 16, 2020
Registry last updated
Jul 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.